<DOC>
	<DOCNO>NCT01958164</DOCNO>
	<brief_summary>This multicentre , open-label , randomise , phase III study design evaluate efficacy safety Actilyse 2 mg/2 ml restoration function CVAD</brief_summary>
	<brief_title>Efficacy Safety Actilyse 2 mg/ 2 ml Comparison Saline Solution Patients With Central Venous Access Device Occlusion</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Inclusion criterion : Male female patient 18 80 year , sign write informed consent Patients central venous access device occlusion , occur within 24h randomisation , central venous access device indicate follow : fluid maintenance , chemotherapy , intravenous feeding , haemodialysis , longterm administration antibiotic medication Patients central venous access device occlusion occur within 24h randomisation . Central venous access device define inability withdraw least 3 ml blood central venous access device . If multiple lumen occlude , investigator choose treat one lumen study . Signed date write informed consent prior admission study accordance good clinical practice local legislation . Acceptable level follow laboratory parameter : hemoglobin ≥ 80 g/L ; total white blood cell count ≥ 2.0 x109/L ; platelet ≥ 50.0 x109/L ; fibrinogen ≥0.5 x low limit normal ; international normalized ratio &lt; 2 x upper limit normal ; activate partial thromboplastin time &lt; 2 x upper limit normal ; total protein ≥ 35 g/l ; alanine transaminase &lt; 20 x upper limit normal ; aspartate transaminase &lt; 20 x upper limit normal ; total bilirubin &lt; 10 x upper limit normal ; creatinine &lt; 6 x upper limit normal ; glucose &gt; 2.8 mmol/l . Exclusion criterion : Any clinical evidence mechanical nonthrombotic occlusion High risk bleed event High risk embolic complication Any condition bleeding constitute significant hazard would particularly difficult manage Administration fibrinolytic agent within 48 hour start study treatment Patients follow within previous 48 hour start study treatment : surgery obstetrical delivery percutaneous biopsy viscera deep tissue puncture noncompressible vessel active internal bleeding Patients thrombocytopenia , hemostatic defect ( include secondary severe hepatic renal disease ) . Pregnancy lactation . Previously know positive result infectious serology Human Immunodeficiency Virus ( HIV ) hepatitis B surface antigen ( HBsAg ) , hepatitis C virus . Known hypersensitivity alteplase gentamicin , excipient Actilyse Body weight &lt; 30 kg . Administration fibrinolytic agent within 48 hour start study treatment . Participation another investigational trial within 30 day prior Screening Visit . Concomitant treatment angiotensinconvertingenzyme inhibitor . Impossibility infuse fluids volume necessary infuse study drug ( 2 ml ) central venous access device .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>